In the present manuscript we assessed the potential value of the MTH1 inhibitors TH588 and (S)-crizotinib in the treatment of patient-derived 3D CRC cultures by head-to-head comparison under normoxia and hypoxia. The gene discussed is NUDT1; the disease is colorectal carcinoma.